Access Oncology is a fully integrated biopharmaceutical company based in New York, NY, dedicated to advancing new hope for people with kidney disease. Their team works tirelessly to address complications associated with kidney disease and has developed a commercially available medicine, as well as a late-stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) called vadadustat, based on Nobel Prize-winning science.
With a mission to protect the kidneys and innovate for better lives, Access Oncology is a trusted leader in the renal community, delivering unique products to patients with kidney disease. Although vadadustat is approved for use in 34 countries, it has not yet received approval from the U.S. Food and Drug Administration.
Generated from the website